Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan

被引：7

作者：

Ito, Keiichi ^{[1
]}

Mikami, Shuji ^{[2
]}

Tatsugami, Katsunori ^{[3
]}

Masumori, Naoya ^{[4
]}

Shinohara, Nobuo ^{[5
]}

Kondo, Tsunenori ^{[6
]}

Nakanishi, Shotaro ^{[7
]}

Nagashima, Yoji ^{[8
]}

Eto, Masatoshi ^{[3
,9
]}

Kamba, Tomomi ^{[9
,10
]}

Kuroda, Naoto ^{[11
]}

Tomita, Yoshihiko ^{[12
,13
]}

Matsuyama, Hideyasu ^{[14
]}

Onishi, Tetsuro ^{[15
]}

Tsushima, Tomoyasu ^{[16
]}

Nakazawa, Hayakazu ^{[17
]}

Oya, Mototsugu ^{[18
]}

Ozono, Seiichiro ^{[19
]}

Naito, Seiji ^{[3
,20
]}

Asano, Tomohiko ^{[1
]}

机构：

[1] Natl Def Med Coll, Dept Urol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan

[2] Keio Univ, Dept Diagnost Pathol, Sch Med, Tokyo, Japan

[3] Kyushu Univ, Dept Urol, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan

[4] Sapporo Med Univ, Dept Urol, Sch Med, Sapporo, Hokkaido, Japan

[5] Hokkaido Univ, Dept Renal & Genitourinary Surg, Grad Sch Med, Sapporo, Hokkaido, Japan

[6] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan

[7] Univ Ryukyus, Dept Urol, Grad Sch Med, Nishihara, Okinawa, Japan

[8] Tokyo Womens Med Univ, Dept Surg Pathol, Tokyo, Japan

[9] Kumamoto Univ, Fac Life Sci, Dept Urol, Kumamoto, Japan

[10] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan

[11] Kochi Red Cross Hosp, Dept Diagnost Pathol, Kochi, Japan

[12] Yamagata Univ, Dept Urol, Fac Med, Yamagata, Japan

[13] Niigata Univ, Grad Sch Med & Dent Sci, Dept Regenerat & Transplant Med, Div Urol, Niigata, Japan

[14] Yamaguchi Univ, Grad Sch Med, Dept Urol, Yamaguchi, Japan

[15] Seirei Citizen Hosp, Dept Urol, Chiba, Japan

[16] NHO Okayama Med Ctr, Div Urol, Okayama, Japan

[17] Tokyo Womens Med Univ, Dept Urol, Med Ctr East, Tokyo, Japan

[18] Keio Univ, Dept Urol, Sch Med, Tokyo, Japan

[19] Hamamatsu Univ Sch Med, Dept Urol, Shizuoka, Japan

[20] Harasanshin Hosp, Dept Urol, Fukuoka, Fukuoka, Japan

来源：

CLINICAL GENITOURINARY CANCER | 2018年 / 16卷 / 06期

关键词：

Central pathologic review; Prognosis; Targeted therapy; Tyrosine kinase inhibitor; INTERFERON-ALPHA; OPEN-LABEL; PHASE-2; TRIAL; SUNITINIB; MULTICENTER; SURVIVAL; IMPACT; TEMSIROLIMUS; EVEROLIMUS; PROGNOSIS;

D O I：

10.1016/j.clgc.2018.07.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We aimed to investigate treatment outcomes in patients with metastatic papillary renal cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other. Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4%), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for >= 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：E1201 / +

页数：14

共 27 条

[1] Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases [J].

Amin, MB ;

Tamboli, P ;

Javidan, J ;

Stricker, H ;

Venturina, MD ;

Deshpande, A ;

Menon, M .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (03) :281-291

[2] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Eisen, Tim ;

Broderick, Samuel ;

Stadler, Walter M. ;

Jones, Robert J. ;

Garcia, Jorge A. ;

Vaishampayan, Ulka N. ;

Picus, Joel ;

Hawkins, Robert E. ;

Hainsworth, John D. ;

Kollmannsberger, Christian K. ;

Logan, Theodore F. ;

Puzanov, Igor ;

Pickering, Lisa M. ;

Ryan, Christopher W. ;

Protheroe, Andrew ;

Lusk, Christine M. ;

Oberg, Sadie ;

George, Daniel J. .

LANCET ONCOLOGY, 2016, 17 (03) :378-388

[3] First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study [J].

Buti, Sebastiano ;

Bersanelli, Melissa ;

Maines, Francesca ;

Facchini, Gaetano ;

Gelsomino, Francesco ;

Zustovich, Fable ;

Santoni, Matteo ;

Verri, Elena ;

De Giorgi, Ugo ;

Masini, Cristina ;

Morelli, Franco ;

Vitale, Maria Giuseppa ;

Sava, Teodoro ;

Prati, Giuseppe ;

Librici, Carmelinda ;

Fraccon, Anna Paola ;

Fornarini, Giuseppe ;

Maruzzo, Marco ;

Leonardi, Francesco ;

Caffo, Orazio .

CLINICAL GENITOURINARY CANCER, 2017, 15 (04) :E609-E614

[4] Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy [J].

Calvo, Emiliano ;

Schmidinger, Manuela ;

Heng, Daniel Y. C. ;

Gruenwald, Viktor ;

Escudier, Bernard .

CANCER TREATMENT REVIEWS, 2016, 50 :109-117

[5]

Choueiri TK, 2008, J CLIN ONCOL, V26, P127, DOI 10.1200/JCO.2007.13.3223

[6] Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies [J].

Dutcher, Janice P. ;

de Souza, Paul ;

McDermott, David ;

Figlin, Robert A. ;

Berkenblit, Anna ;

Thiele, Alexandra ;

Krygowski, Mizue ;

Strahs, Andrew ;

Feingold, Jay ;

Hudes, Gary .

MEDICAL ONCOLOGY, 2009, 26 (02) :202-209

[7] Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis [J].

Escudier, Bernard ;

Molinie, Vincent ;

Bracarda, Sergio ;

Maroto, Pablo ;

Szczylik, Cezary ;

Nathan, Paul ;

Negrier, Sylvie ;

Weiss, Claudia ;

Porta, Camillo ;

Gruenwald, Viktor ;

Albiges, Laurence .

EUROPEAN JOURNAL OF CANCER, 2016, 69 :226-235

[8] Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial [J].

Gore, Martin E. ;

Szczylik, Cezary ;

Porta, Camillo ;

Bracarda, Sergio ;

Bjarnason, Georg A. ;

Oudard, Stephane ;

Hariharan, Subramanian ;

Lee, Se-Hoon ;

Haanen, John ;

Castellano, Daniel ;

Vrdoljak, Eduard ;

Schoffski, Patrick ;

Mainwaring, Paul ;

Nieto, Alejandra ;

Yuan, Jinyu ;

Bukowski, Ronald .

LANCET ONCOLOGY, 2009, 10 (08) :757-763

[9] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[10] Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma [J].

Ito, Keiichi ;

Asano, Tomohiko ;

Yoshii, Hidehiko ;

Satoh, Akinori ;

Sumitomo, Makoto ;

Hayakawa, Masamichi .

INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (11) :1365-1370

← 1 2 3 →